High-throughput metagenomic sequencing offers an unbiased approach to identify pathogens in clinical samples. Conventional metagenomic sequencing however does not integrate information about the host, which is often critical to distinguish infection from infectious disease, and to assess the severity of disease. Here, we explore the utility of high-throughput sequencing of cell-free DNA after bisulfite conversion to map the tissue and cell types of origin of host-derived cell-free DNA, and to profile the bacterial and viral metagenome. We applied this assay to 51 urinary cfDNA isolates collected from a cohort of kidney transplant recipients with and without bacterial and viral infection of the urinary tract. We find that the cell and tissue types of origin of urinary cell-free DNA can be derived from its genome-wide profile of methylation marks, and strongly depend on infection status. We find evidence of kidney and bladder tissue damage due to viral and bacterial infection, respectively, and of the recruitment of neutrophils to the urinary tract during infection. Through direct comparison to conventional metagenomic sequencing as well as clinical tests of infection, we find this assay accurately captures the bacterial and viral composition of the sample. The assay presented here is straightforward to implement, offers a systems view into bacterial and viral infections of the urinary tract, and can find future use as a tool for the differential diagnosis of infections.
Differential diagnosis of infectious disease in humans is complex. Metagenomic high-throughput 3 DNA sequencing offers an unbiased approach for the detection of pathogens in clinical samples 1-4 4 , but the presence of a pathogen is not necessarily synonymous with disease 5 . Some microbes 5 are commensals in all human hosts, some only cause disease in some hosts, and others cause 6 disease in all hosts. To bring clarity to the lexicon of microbial pathogenesis, Casadevall and 7 Pirofski defined infectious disease as a clinical manifestation of damage to the host that results 8 from host-microbe interaction 5, 6 . In this framework, the degree of host damage, mediated by the 9 host response and/or by the pathogen, offers a quantifiable metric that can be used to distinguish 10 between different outcomes of infection 6 . 11 12 We report a high-throughput metagenomic sequencing assay that can both detect a diverse array 13 of bacterial and viral pathogens and quantify damage to host tissues. The assay implements 14 whole-genome bisulfite sequencing (WGBS) of cell-free DNA (cfDNA), small fragments of DNA 15 released by host or microbial cells into blood, urine and other bodily fluids, and brings together 16 two previously reported concepts. First, the assay implements a genome-wide measurement of 17 cytosine methylation marks comprised within cfDNA -marks that are highly cell, tissue and organ-18 type specific -to determine the cell and tissue types that contribute to the mixture of host cfDNA 19 in a sample. Several recent studies have shown that profiling CpG methylation marks in urinary 20 or plasma cfDNA, via whole-genome sequencing, targeted sequencing, or PCR assays, can be 21 used to determine their tissues-of-origin and to quantify tissue-specific injury in various diseased 22 settings [7] [8] [9] . Here, we explore this concept for the monitoring of injury due to infection. Second, 23 the assay quantifies the relative abundance of microbes via WGBS of cfDNA. Several studies 24 have investigated the utility of conventional, metagenomic sequencing of cfDNA for infection 25 testing in clinical samples 2, 4, 10, 11 . We show here that WGBS is compatible with such analyses. 26 27 We investigated the utility of this assay to monitor infectious complications of the urinary tract 28 after kidney transplantation. More than 80,000 patients receive lifesaving kidney transplants 29 worldwide each year 12 . Immunosuppression after transplantation is required to manage the risk 30 of rejection but leaves patients vulnerable to viral and bacterial infection. BK Polyomavirus (BKV) 31 infection has emerged as serious risk factor for allograft survival. BKV reactivation occurs in up 32 to 73% of kidney transplant recipients, and leads to BK Polyomavirus Nephropathy (BKVN) in up 33 to 8% of patients 13, 14 . Renal biopsies are currently required to confirm BKVN and to distinguish 34 BKVN from BKV reactivation without nephropathy (BKV+/N-). While BKVN histology is 35 characterized by inflammation and necrosis of tissue, biopsies from BKV+/N-patients are similar 36 to those without reactivation 13 . It remains unclear whether BKV reactivation alone induces kidney 37 damage. Bacterial urinary tract infection (UTI) affects approximately 43% of kidney transplant 38 recipients in the first 42 months post-transplant 15 . There is a disagreement in the literature 39 regarding the appropriate balance between mitigating the risks of infectious complications and 40 adverse effects of antimicrobial treatment for UTI. In this study, we describe a urinary cfDNA 41 assay that can identify viral and bacterial infectious agents and can quantify the degree of host 42 injury related to UTI. 43 44
RESULTS
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Methylation marks are cell, tissue and organ type specific 3 4 We performed WGBS (Fig. 1a) on 51 urinary cfDNA isolates collected from a cohort of kidney 5 transplant recipients (Fig.1b) and used computational methods to quantify the burden of viral and 6 bacterial cfDNA and the cell and tissue types of origin of host-derived cfDNA (Fig.1c) . We 7 assayed urinary cfDNA isolates from patients who had a same-day corresponding bacterial 8 culture (UTI positive, UTI group, n=12; UTI negative, no-UTI group, n=12), and from patients that 9
were BKV positive in the blood and confirmed to have BKVN by biopsy (BKVN, n=9), BKV positive 10 in the blood without evidence of BKVN on biopsy (BKVN+/N-, n=7) and negative for BKV in the 11 blood and with normal surveillance biopsy (Normal, n=6). In addition, we analyzed urinary cfDNA 12 obtained from patients within the first three days after transplantation (Early group, n=5). To obtain 13 sequence information after bisulfite conversion of these molecules, we used a single-stranded 14 sequencing library preparation 1, 16 (Fig. 1a) . This library preparation employs ssDNA adapters and 15 bead ligation to create diverse sequencing libraries from short, highly fragmented cfDNA 16, 17 with three heterogeneous clusters representing blood, gut and a diverse group of other solid organ 28 tissues (Fig.1d, Supplemental Fig. 1 ). To identify both global and local structural features within 29 reference methylomes, we applied uniform manifold approximation projection (UMAP) 24 . We 30 found that UMAP further resolves reference methylation profiles into clusters comprised of 31 specific cell-types (Fig. 1d,e Figure 1 . Study methodology and cell type specificity of genome-wide methylation profiles. a Schematic of single-stranded library preparation method. cfDNA is denatured and treated with sodium bisulfite, which converts unmethylated cytosines (dark blue) into uracils (light blue) but not methylated cytosines (green). Bisulfite-treated DNA is first ligated to singlestranded adapters and bound to magnetic beads. Second-strand synthesis, and doublestranded adapter ligation are performed on the beads. The final step is a PCR, which converts uracils to thymines (red). b Pie chart with summary of samples included in this study, colored by pathology. c Schematic of WGBS analysis workflow. d Principal component analysis of reference whole-genome methylation profiles from human tissues. e Uniform manifold approximation projection of reference methylation profiles. Ellipses in d, e are normal 95% confidence ellipses (K-means, 4 centers).
Cell-free DNA origin associated with infection 1 2
To determine methylation marks comprised within urinary cfDNA, we first aligned the WGBS 3 reads to a human reference genome via bwa-meth 28 . We quantified the efficiency of bisulfite 4 conversion achieved in experiments from the fraction of reported methylated C[A/T/C] base pairs, 5 which are rarely methylated in humans 29 . We found a conversion efficiency greater or equal to 6 94.5% for all cfDNA isolates (see Methods). We next projected the genome-wide cfDNA CpG 7 methylation profiles onto the two-dimensional feature spaces generated by PCA and UMAP for 8 the 112 public references. We found that cfDNA profiles organized between the cluster that 9 comprised kidney tissue and the white blood cell cluster on the PCA and UMAP two-dimensional 10 projections (Fig. 2 a,b) . This observation provided a first indication that urinary cfDNA originates 11
primarily from blood cell types and kidney tissue. Other cell types found in the urinary tract 12 contributed less significantly to urinary cfDNA. 13 14 We 33 . Using this approach, 35 we found an excellent quantitative agreement (Spearman's rho=0.88, p-value < 2.2x10 -16 , Fig.  36 2c) between the proportion of kidney specific cfDNA (determined from methylation marks) and 37 ddcfDNA (determined from genetic marks in cfDNA) for sex-mismatched donor-recipient 38 transplant pairs (n=44). This analysis provided support for the use of our bioinformatic and 39 molecular approaches to quantify the tissue and cell types of origin of cfDNA in urine. 40 41 We proceeded to analyze the relative contributions of all cell and tissue types comprised within 42 the pure cell and tissue references against clinical tests of infection. We found that the cfDNA cell 43 and tissue composition was associated with infection status (Fig. 2d) . For example, the relative 44 contribution of kidney-derived cfDNA was elevated in samples from patients with BKV infection 1 compared to patients diagnosed with bacterial UTI (p-value = 2.0x10 -4 , mean of 48.6%; mean 2 12.5%, respectively , Fig. 2d ). We further found that leukocytes were enriched in samples from 3 patients diagnosed with bacterial UTI by conventional culture, and that neutrophils are the main 4 contributors to the differences in white blood cell content, as expected from their role as first 5 responders to infection (Fig. 2d) 34 . 6 7 Figure 2 . Methylation marks within cfDNA inform its tissues-of-origin. a, b Projection of cfDNA genome-wide methylation profiles onto PCA and UMAP feature space (from Fig. 1d ,e). Data points colored according to donor fraction (n=44). c Comparison of the proportion of kidney-derived cfDNA and donor-derived cfDNA measured for sex-mismatched donorrecipient pairs (n=44). Spearman's rho=0.88, p-value < 2.2x10 -16 . Samples from dual bonemarrow and kidney transplants are excluded. d Barplot of cfDNA cell and tissue type composition measured for clinical groups.
The relative proportion of cfDNA from a specific tissue is a function of the proportion of DNA 1 released from all other cell types or tissues and may therefore be a convoluted measure of tissue-2 specific injury. To overcome this limitation, we computed the absolute concentration of tissue-3 specific cfDNA by multiplying the proportion of tissue and cell type specific DNA obtained using 4 the approaches above with the concentration of total host-derived cfDNA in the sample (see 5 Methods). We observed marked temporal dynamics of the concentration of cfDNA from different 6 cell and tissue types in absence of infection (no-UTI, Normal and Early groups, Fig. 3a ). Recovery 7 of postoperative stress in the first three days after transplantation was associated with a marked 8 increase in cfDNA from most tissues. This signal of early post-operative injury decayed to a low 9 baseline within 10 days after transplantation, and after three months post transplantation 10 quiescence was observed with markedly low amount of cfDNA from all cell and tissue types in 11 absence of infection. 12 13 We examined whether the cfDNA concentration of certain tissues was associated with infection 14 pathology. We first examined all samples from patients that were screened for BKVN via needle 15 biopsy (all samples collected after day 100). We observed marked differences in the concentration 16 of kidney-derived cfDNA for samples from patients diagnosed with BKVN (BKVN vs Normal, mean 17 kidney cfDNA 21.9 ng/ml, and 1.5ng/ml, respectively p-value = 4.0x10 -4 , Fig. 3b ), indicating 18 significant tissue injury associated with BKVN. In addition, we found that this cfDNA measurement 19 can distinguish BKVN from BKV reactivation without nephropathy (BKVN vs BKV+/N-, mean 20 kidney cfDNA 21.9 ng/ml and 6.9 ng/ml, respectively, p-value = 7.9x10 -3
), and BKV+/N-from 21
Normal (mean kidney cfDNA 6.9 ng/ml and 1.5ng/ml, respectively, p-value = 1.2x10
). The 22 concentration of leukocyte cfDNA was elevated in urine from patients diagnosed with BKVN 23 (mean 19.0 ng/ml vs. 1.9 ng/ml in Normal, p-value = 2.8x10
) and BKV+/N-(mean 4.0 ng/ml vs. 24 1.9 ng/ml, p-value = 3.5x10 ) (Fig. 3c) . Together these experiments point to the utility of the 26 assay presented here to non-invasively distinguish nephropathy and inflammation due to BK virus 27 infection. The kidney cfDNA concentration in samples collected from patients within the first three 28 days after transplantation, a period during which we observed significant post-operative injury 29 ( Fig. 3a) , was also elevated (12.4 ng/ml) and could not be differentiated from the concentration 30 measured in samples from patients with BK disease (p-value=0.30 and 0.20 when compared to 31 BKVN and BKV+/N-, respectively). This last observation underlines the importance of paired 32 metagenomic evaluation to distinguish infection and non-infection related host injury. 33 34 We next evaluated all samples from patients that were screened for UTI via conventional urine 35 culture (no-UTI group and UTI group, n=12 each). These samples were collected between days 36 8 and 55 post-transplant, a period in which we observed significant host injury in absence of 37 infection (Fig. 3a) , and were evaluated for hematuria by microscopy, a clinical marker of injury. 38 We found that both bladder and leukocyte-derived cfDNA were elevated in samples from patients 39 diagnosed with bacterial UTI and hematuria (Red Blood Cell [RBC] counts per High Power Field 40
[HPF] greater than 4) compared to patients diagnosed with UTI in the absence of hematuria ( Fig.  41 3d, receiver operator characteristic analysis, area under the curve [AUC] = 0.91 for bladder 42 cfDNA). We further found correlations between red blood cell (RBC) counts and the 43 concentrations of bladder cfDNA in urine (all samples for which RBC per HPF was measured, 44 n=24, Spearman's rho = 0.43, p-value = 3.5x10 -2 ). Together, these observations demonstrate the 1 utility of our assay to assess the severity of injury due to bacterial UTI. The performance of the 2 concentration of bladder cfDNA in distinguishing bacterial UTI and absence of UTI with and 3 without hematuria was modest (AUC = 0.64 for bladder cfDNA, Fig. 3d ), which is likely explained 4 by the significant non-infection related injury in this patient population in the sample time window. 5 6
Last, we asked whether the concentration of kidney derived cfDNA correlated with serum 7 creatinine, a clinical marker of kidney function. Creatinine is a waste product of muscle 8 metabolism and elevated serum creatinine levels are an indication of poor kidney function. We 9 found good agreement between kidney-specific cfDNA in urine and serum creatinine (all samples 10 for which serum creatinine was measured, n = 50, Spearman's rho=0.51, p-value=1.5x10 -4 ). 11
Together, the data presented in Figure 3 provide strong support for the use of WGBS of cfDNA 12 to quantify host injury due to viral and bacterial UTI. 13 14 The pattern of degradation of cfDNA in plasma has previously been shown to depend on their 15 origin and pathology. For example, tumor-derived cfDNA was found to be significantly shorter 16 than cfDNA from normal tissue 35, 36 . Here, we sized urinary cfDNA using paired-end read mapping 17 (see Methods). Bisulfite treatment is known to lead to DNA degradation 37 , and this was 18 corroborated by our cfDNA sizing assay. We found that bisulfite-treated cfDNA is on average 10.1 19 bp shorter than untreated cfDNA (n = 38 matched samples). We furthermore found that the mean 20 fragment length of host-derived cfDNA was negatively correlated with the white blood cell 21
proportion (Spearman's rho = -0.45, p-value = 1.1x10 -3 , n=51) and was shorter for samples from 22 patients with bacterial infection than from patients without bacterial UTI (p-value = 2.4x10 -2 , mean 23 length of 93 and 101bp, respectively, Fig. 3f, Supplemental Fig. 3 ). This observation is in line 24 with previous reports that leukocytes create a degradative environment for DNA 38, 39 . The fragment 25 size profile of cfDNA may offer an additional metric by which patients with different infectious 26 pathologies can be stratified. 27 28
Whole genome bisulfite sequencing of cfDNA identifies clinically-relevant pathogens 3 4
Bisulfite conversion of DNA followed by PCR converts unmethylated cytosines into thymines. A 5 corollary of bisulfite treatment is a decrease in cytosine content, and a reduction in overall read 6 complexity. To determine whether WGBS can be used to identify specific uropathogens despite 7 the reduction in sequence complexity inherent to bisulfite conversion, we compared pathogen 8 abundances measured after shotgun sequencing of bisulfite-treated and untreated cfDNA 9 (matched samples, n=38). We determined the relative representation of bacteria and viruses in 10 these datasets, using approaches previously described 2,3,40 (see Methods). We computed the 11 representation of microbial genomes relative to human genome copies and expressed this 12 quantity as relative genome equivalents (RGE, see Methods). Figure 4a shows a close 13 Inset shows receiver operating characteristic analysis of the performance of bladder cfDNA in distinguishing no-UTI from UTI groups (blue) and in distinguishing hematuria (RBC per HPF >4) from no hematuria (RBC per RBC ≤4) in samples from the UTI group. e Serum creatinine versus kidney urinary cfDNA concentration (n=50). Spearman's rho=0.51 p-value=1.4x10 -4 . f Mean host cfDNA fragment length versus leukocyte proportion (n=51). Spearman's rho=-0.45, p-value=1.1x10 -3 . Inset shows boxplots of fragment lengths measured for the UTI and no-UTI groups. Boxplot features detailed in the Methods section. * p-value< 0.05, ** p-value< 0.01, *** p-value< 0.001.
quantitative agreement between the species abundance measured for bisulfite-treated and 1 untreated cfDNA, confirming that it is possible to broadly identify microbial cfDNA via shotgun 2 sequencing of bisulfite-treated cfDNA (Fig. 4a , Spearman's rho = 0.72, p-value < 2.2x10 -16 ). 3 4 We assessed the relative genomic abundance of cfDNA from bacterial and viral pathogens 5 identified by conventional diagnostic assays. In 9 out of 9 BKVN samples and 6 out of 7 BKV+/N-6 samples, we identified high BK viral loads (RGE > 10 3 , Fig. 4b) . These values correlated strongly 7 with matched plasma BKV copies as determined by quantitative PCR (Spearman's rho=0.81, p-8 value=6.2x10 -6 ). We next compared the relative genomic abundance of bacterial cfDNA for 9 patients diagnosed with bacterial infection (12 samples matched with a positive clean-catch 10 midstream urine culture, UTI group), to the relative genomic abundance measured for 12 negative 11 clean-catch midstream urine cultures (no-UTI group We have described a metagenomic assay that simultaneously quantifies the abundance of a large 5 array of viruses and bacteria in clinical samples, and the degree of host injury. This work is 6 motivated by the need to integrate information about host-microbe interactions in clinical 7 metagenomic assays in order to distinguish infection from infectious disease, and to assess the 8 severity of disease. The assay reported here takes advantage of genome-wide profiling of CpG 9 methylation marks comprised within cfDNA to quantify the contributions of different cell and tissue 10 types to the mixture of cfDNA in the sample, and thereby the degree of host damage. Compared 11 to conventional metagenomic cfDNA assays 2, 41 , this assay requires a single additional 12 experimental step, bisulfite treatment of the cfDNA isolate, which is inexpensive and can be 13
completed within approximately two hours. 14 15 We tested the utility of this assay to monitor viral and bacterial infections of the urinary tract in a 16 cohort of kidney transplant recipients. We found that the concentration of cfDNA derived from 17 group. BKV reactivation without nephropathy was also characterized by elevated levels of kidney-3 specific DNA but not to the same degree as BKVN. Our findings suggest that there may be kidney 4 damage occurring before the onset of nephropathy. Biopsies only provide information on the 5 sampled region of the kidney, and do not capture the inherent heterogeneity of BKV infection 6 within the kidney allograft and disease progression. The assay described here may find use as a 7 noninvasive alternative to conventional biopsy to screen for BKV related kidney injury. 8 9 In . Here, we have applied 24 this technology for the first time to the monitoring of host tissue damage due to infection. 25 Host-based molecular signatures have previously been considered as classifiers of infectious 26 complications. In respiratory infection, host transcriptional profiling of the peripheral blood has 27 been shown to provide a means to characterize the host response to viral and bacterial infection, 28 and to discriminate between infectious and noninfected states 46 . Host-response molecular 29 signatures thereby offer a diagnostic approach orthogonal to approaches that focus on viral and 30 bacterial pathogens. Recently, Langelier et al. described a diagnostic approach that combines 31 transcriptional profiling and metagenomic sequencing of tracheal aspirate to classify lower 32 respiratory tract infection 47 . Here, we show that a cfDNA assay can be used to screen for 33 infectious agents and to quantify the degree of host damage. The strength of this assay lies in its 34 simplicity of implementation, its noninvasiveness, and its ability to directly interrogate host 35 damage, the metric that is most relevant to classify infectious complications in the framework 36 proposed by Casadevall and Pirofski 5 . 37 38 In summary, we propose that WGBS of cfDNA can be used as a metagenomic sequencing assay 39 to provide in depth understanding of both the metagenome as well as the host response to 40
infection. This assay is generalizable to multiple diseased states and has the potential to 41 distinguish colonization from infectious disease in a clinical setting. 42 43 Twenty-two urine samples from 21 patients were collected at the time of kidney allograft biopsy; 8 9 samples were collected from patients with BK viremia were found to have BK polyomavirus 9 nephropathy with positive immunohistochemical staining for SV40 large T antigen (BKVN), 7 10 samples from patients with BK viremia were found not to have BK polyomavirus nephropathy 11
(BKV+/N-) and 6 patients did not have BK viremia and had no significant pathology in the biopsies 12 (Normal). 13 14 Plasma BKV copies per ml of blood were measured using the quantitative assay developed by 15 Quest Diagnostics as part of clinical testing. 16 17 Renal Allograft Biopsy Evaluation: Percutaneous core needle biopsy specimens of kidney 18 allografts were fixed in 10% buffered formalin and embedded in paraffin. Tissues-of-origin deconvolution. Tissues and cell-types of origin were determined by quadratic 5 programming 58, 59 according to the following equation:
Where A is an (m+1) x n matrix with m cell and tissue methylation references spanning n DMRs. 10 The additional column contains an error parameter to consider potential missing references, Figure S1 . Principal component analysis of reference methylomes. 14 Figure S2 . Scatterplot of corresponding donor fractions in sex-mismatched samples that 15 underwent both WGBS and standard sequencing. 16 Figure S3 . Mean fragment length of bisulfite-treated cfDNA for BKVN, BKV+/N-, Normal, no-UTI, 17 UTI and Early groups. 18 Table S1 . Reference methylation dataset metadata 19 Table S2 . Clinical information of urine samples 20 21 COMPETING FINANCIAL INTERESTS 22
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